All News

Retrophin's enteric-coated formulation allows administration with or without food.

Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria.

This funding is part of an effort to provide technical assistance to enhance efforts to end the HIV epidemic.

Technology solutions such as CourMed will allow better pharmacist-patient communication, adherence, and overall improved patient outcomes.

Pharmacists are taking to social media in response to layoffs at Walmart pharmacies across the country.

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.

Fewer than 40% of people have ever had a HIV test, and less than 30% of people in the United States most at risk of acquiring HIV were tested in the past year.

First-line treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) demonstrated overall and progression-free long-term survival benefits in patients with BRAF-mutation positive melanoma.

Top news of the day from across the health care landscape.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

In a prepared statement, Pharmacy Quality Alliance (PQA) Chief Executive Officer Laura Cranston, RPh, said the organization applauds the initiatives outlined in “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.”

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

The advisory board voted unanimously on Wednesday to recommend HPV vaccines for people through age 26.

Officials with the FDA have approved Dova Pharmaceuticals’ supplemental New Drug Application (sNDA) for expanding the use of avatrombopag (Doptelet).

Avatrombopag was previously approved by the agency for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.

Data from a phase 2 study demonstrated that topical ruxolitinib cream significantly improved repigmentation of facial lesions in adults with vitiligo.

Top news of the day from across the health care landscape.

CRSwNP often occurs with severe asthma and requires systemic steroids or nasal surgery, the current standard of care.

Dupilumab (Dupixent) is the first biologic medicine approved for inadequately controlled chronic rhinosinusitis with nasal polyposis.

To date, the Ohio audit is the first comprehensive review of PBM practices and incorporated 39 million drug transactions, the authors said.

The drug is earned the designation for reducing the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

The recently-finalized CMS drug pricing rule excluded direct and indirect remuneration fee reform.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

Removal of the offending agent(s) is the first step in treatment for acquired methemoglobinemia.